|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0019167,
umls-concept:C0205195,
umls-concept:C0205466,
umls-concept:C0209738,
umls-concept:C0524909,
umls-concept:C0796545,
umls-concept:C0871261,
umls-concept:C1446409,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2007-8-23
|
|
pubmed:abstractText |
To investigate whether simultaneous commencement of peginterferon alpha-2b and lamivudine treatment has more potent hepatitis B virus (HBV) DNA suppression than staggered regimes.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1359-6535
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
815-23
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17713165-Adult,
pubmed-meshheading:17713165-Antiviral Agents,
pubmed-meshheading:17713165-DNA, Viral,
pubmed-meshheading:17713165-Drug Administration Schedule,
pubmed-meshheading:17713165-Drug Resistance, Viral,
pubmed-meshheading:17713165-Drug Therapy, Combination,
pubmed-meshheading:17713165-Female,
pubmed-meshheading:17713165-Hepatitis B, Chronic,
pubmed-meshheading:17713165-Hepatitis B e Antigens,
pubmed-meshheading:17713165-Hepatitis B virus,
pubmed-meshheading:17713165-Humans,
pubmed-meshheading:17713165-Interferon-alpha,
pubmed-meshheading:17713165-Lamivudine,
pubmed-meshheading:17713165-Liver,
pubmed-meshheading:17713165-Male,
pubmed-meshheading:17713165-Middle Aged,
pubmed-meshheading:17713165-Pilot Projects,
pubmed-meshheading:17713165-Polyethylene Glycols,
pubmed-meshheading:17713165-Recombinant Proteins,
pubmed-meshheading:17713165-Time Factors,
pubmed-meshheading:17713165-Treatment Outcome,
pubmed-meshheading:17713165-Viral Load,
pubmed-meshheading:17713165-Virus Replication
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B.
|
|
pubmed:affiliation |
Institute of Digestive Disease and Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China. hlychan@cuhk.edu.hk
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
